Non Alcoholic Fatty Liver Disease Treatment Market

Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-alcohol. Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of non-alcoholic fatty liver disease (NAFLD) is unknown. The nonalcoholic fatty liver disease (NAFLD) is one of the most common diseases in the United States. The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising due to rise in prevalence of diabetes and obesity. According to National Health and Nutrition Examination survey, about 20-30% of the general population in the western world suffer from nonalcoholic fatty liver disease (NAFLD). The common symptoms include fatigue, weakness, weight loss and others. The diagnosis of NAFLD requires the combination of different tests such as blood test, ultrasound, CT scan, MRI scan, and liver biopsy. The two types of Nonalcoholic fatty liver disease (NAFLD) includes simple fatty liver and Nonalcoholic Steatohepatitis (NASH). The simple fatty liver is a type of nonalcoholic fatty liver (NAFL), in which fat is deposited, but no inflammation or liver damage is observed. NASH is the inflammation of the liver due to excess fat deposit and can lead to liver damage and disease.

Non Alcoholic Fatty Liver Disease Treatment Market contains market size and forecasts of Non Alcoholic Fatty Liver Disease Treatment in Global, including the following market information:

Global Non Alcoholic Fatty Liver Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Non Alcoholic Fatty Liver Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Antioxidants Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Non Alcoholic Fatty Liver Disease Treatment include Pfizer, Roche, Daewoong, Cardax, Merck, Novartis, Gilead Sciences, AstraZeneca and Limerick BioPharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Non Alcoholic Fatty Liver Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Non Alcoholic Fatty Liver Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Non Alcoholic Fatty Liver Disease Treatment Market Segment Percentages, by Type, 2021 (%)

Antioxidants

Thiazolidinedione

Biguanides

Lipid lowering Agents

FXR Receptor Agonist

Others

Global Non Alcoholic Fatty Liver Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Non Alcoholic Fatty Liver Disease Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacy

Retail Pharmacy

Drug Stores

Online Pharmacy

Others

Global Non Alcoholic Fatty Liver Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Non Alcoholic Fatty Liver Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Non Alcoholic Fatty Liver Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Non Alcoholic Fatty Liver Disease Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Roche

Daewoong

Cardax

Merck

Novartis

Gilead Sciences

AstraZeneca

Limerick BioPharma

GW Pharmaceuticals

Allergan

Takeda Pharmaceutical